4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
8.60
-0.09 (-1.04%)
At close: May 22, 2026, 4:00 PM EDT
8.57
-0.03 (-0.35%)
After-hours: May 22, 2026, 6:14 PM EDT

4D Molecular Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
88.2485.210.0420.723.1318.04
Revenue Growth (YoY)
383560.87%230194.59%-99.82%562.29%-82.65%32.52%
Gross Profit
88.2485.210.0420.723.1318.04
Selling, General & Admin
47.8149.0646.5836.4932.9128.01
Research & Development
219.98195.7141.397.180.2561.36
Total Operating Expenses
267.79244.76187.88133.59113.1689.37
Operating Income
-179.55-159.55-187.84-112.87-110.03-71.33
Interest Income
18.7619.4827.0512.212.570.14
Other Non-Operating Income (Expense)
-0.08-0.04-0.08-0.18-0.04-0.12
Total Non-Operating Income (Expense)
18.6819.4426.9712.032.540.02
Pretax Income
-160.87-140.11-160.87-100.84-107.49-71.32
Net Income
-160.9-140.11-160.87-100.84-107.49-71.32
Net Income to Common
-160.9-140.11-160.87-100.84-107.49-71.32
Shares Outstanding (Basic)
615854393228
Shares Outstanding (Diluted)
615854393228
Shares Change (YoY)
9.82%7.39%37.86%20.95%16.66%331.23%
EPS (Basic)
-2.57-2.42-2.98-2.58-3.32-2.57
EPS (Diluted)
-2.57-2.42-2.98-2.58-3.32-2.57
Shares Outstanding
52.2757.6145.7943.0832.6332.22
Free Cash Flow
-129.34-109.62-138.37-78.56-98.22-78.24
Free Cash Flow Per Share
-2.12-1.89-2.57-2.01-3.04-2.82
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-203.47%-187.24%-507678.00%-544.65%-3516.52%-395.46%
Profit Margin
-182.31%-164.43%-434778.00%-486.59%-3435.41%-395.37%
FCF Margin
-146.58%-128.65%-373976.00%-379.11%-3139.05%-433.77%
EBITDA
-171.62-151.92-181.14-107.12-106.15-68.31
EBITDA Margin
-194.49%-178.29%-489557.00%-516.90%-3392.52%-378.72%
EBIT
-179.55-159.55-187.84-112.87-110.03-71.33
EBIT Margin
-203.47%-187.24%-507678.00%-544.65%-3516.52%-395.46%
Updated May 7, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q